NCT03690388 · Interventional trial
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Overall registry status Active not recruiting
Phase 3
Conditions Differentiated Thyroid Cancer
Delaware Valley sites
- Exelixis Clinical Site #1 · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory